A mutation was constructed in the CAP homology domain of yeast topoisomerase II that resulted in hypersensitivity to the intercalating agent N-[4-(9-acridinylamino)-3-methoxy-phenyl]methanesulfonamide and the fluoroquinolone 6,8-difluoro-7-(4-hydroxyphenyl)-1-cyclopropyl-4-quinolone-3-carboxylic acid, but not to etoposide. This mutation, which changes threonine at position 744 to proline, also confers hypersensitivity to anti-bacterial fluoroquinolones. The purified T744P mutant protein had wild type enzymatic activity in the absence of drugs, and no alteration in drug-independent DNA cleavage. Enhanced DNA cleavage in the presence of N-[4-(9-acridinylamino)-3-methoxy-phenyl]methanesulfonamide and fluoroquinolones was observed, in agreement with the results observed in vivo. DNA cleavage was also seen in the presence of norfloxacin and oxolinic acid, two quinolones that are inactive against eukaryotic topoisomerase II. The hypersensitivity was not associated with heat-stable covalent complexes, as was seen in another drug-hypersensitive mutant. Molecular modeling suggests that the mutation in the CAP homology domain may displace amino acids that play important roles in catalysis by topoisomerase II and may explain the drug-hypersensitive phenotype.
DNA topoisomerases are enzymes that catalyze changes in the topology of DNA by transiently breaking phosphodiester bonds in the DNA backbone (1) . Two major classes of topoisomerases have been identified, type I enzymes, which introduce single strand breaks in DNA, and type II enzymes, which introduce transient double strand breaks. The ability of these enzymes to resolve the winding problems that arise during nucleic acid metabolism render them essential for many of DNA metabolic processes including transcription, DNA replication, and chromosome segregation. Both type I and type II enzymes are ubiquitous among both prokaryotes and eukaryotes, and recent work has led to the discovery of several novel topoisomerases with novel biochemical properties and important specialized physiological roles (reviewed in Ref. 2) .
In addition to their numerous biological functions, topoisomerases are important targets for both anti-bacterial agents and anti-cancer chemotherapeutic agents (reviewed in Refs. [3] [4] [5] . Most of the topoisomerase targeting drugs in clinical use are topoisomerase poisons, agents that lead to enhanced levels of an intermediate of the topoisomerase reaction where the enzyme is covalently bound to DNA by a phosphotyrosine linkage and the DNA strand scission has occurred (4) . Extensive evidence supports the hypothesis that topoisomerase poisons kill cells because of the DNA damage generated by the covalent complex rather than by depriving cells of an essential enzymatic activity (3, 6) . Therefore, resistance to topoisomerase poisons can occur by a change in the level of protein-DNA covalent complexes that arise in the presence of drug, either by reduced activity of the enzyme or by an intrinsic change in sensitivity of the enzyme to the poison.
Eukaryotic topoisomerase I is the target of camptothecins, whereas eukaryotic topoisomerase II is the target of numerous agents including DNA intercalating agents such as the anthracycline doxorubicin and nonintercalating agents such as the epipodophyllotoxin etoposide. Prokaryotic topoisomerase II is the target of fluoroquinolones, which are important broad spectrum anti-bacterial agents (7, 8) . Although most fluoroquinolones that have been described are highly specific for prokaryotic type II topoisomerases, several agents have been described that are also very active against eukaryotic topoisomerase II (9, 10). Notably, 6,8-difluoro-7-(4Ј-hydroxyphenyl)-1-cyclopropyl-4-quinolone-3-carboxylic acid (CP-115,953), 1 a fluoroquinolone closely related to ciprofloxacin, is a potent eukaryotic topoisomerase II poison (10, 11) . Studies in yeast demonstrated that TOP2 is the primary physiological target for this quinolone (12) .
In Escherichia coli, mutations that lead to quinolone resistance are most often found in gyrA, the structural gene for the DNA gyrase A subunit. Ser 83 of gyrA is the amino acid most frequently changed in strains with high levels of quinolone resistance. E. coli also expresses an additional fluoroquinolone sensitive type II topoisomerase, encoded by the parC and parE genes (13, 14) . The parC locus is homologous to gyrA, and mutations in parC at sites analogous to quinolone-resistant gyrase mutations are also associated with fluoroquinolone resistance in E. coli and other bacteria (15) (16) (17) (18) . Proteins bearing Ser 83 mutations have essentially normal gyrase activity but have decreased affinity for fluoroquinolones (19, 20) . In addition to the sites in gyrA or parC, mutations have also been found in gyrB that lead to quinolone resistance, which has led to the suggestion that domains in gyrA and gyrB collaborate to form a quinolone-binding pocket (21) (22) (23) .
A wide range of mutations have been isolated in eukaryotic topoisomerase II leading to resistance to topoisomerase targeting drugs (reviewed in Ref. 24) . Mutations are found in regions of eukaryotic topoisomerase II that are homologous to gyrB and gyrA as well as in other regions of the protein. However, few mutations have been described that make the enzymes more sensitive to topoisomerase poisons (25) (26) (27) . Because mutations that render the enzyme more resistant to poisons can occur by a variety of ways, including reduction in enzyme activity, drugresistant mutations may not be informative about the mechanisms of actions of drugs (28, 29) . Drug-hypersensitive mutations may therefore be a uniquely useful set of tools for probing drug mechanisms. In this report, we describe a mutation in yeast topoisomerase II that renders the enzyme hypersensitive to multiple classes of topoisomerase II poisons, including intercalating agents and fluoroquinolones.
EXPERIMENTAL PROCEDURES
Yeast Strains and Plasmids-All experiments for assessing drug sensitivity were carried out in JN362a (MATa ura3-52 leu2 trp1 his7 ade1-2 ISE2) or its isogenic rad52 Ϫ and top2-4 derivatives, JN362at2-4, (MATa ura3-52 leu2 trp1 his7 ade1-2 ISE2 top2-4), JN394 (MATa ura3-52 leu2 trp1 his7 ade1-2 ISE2 rad52::LEU2), and JN394t2-4 (MATa ura3-52 leu2 trp1 his7 ade1-2 ISE2 rad52::LEU2 top2-4). Yeast Top2p was purified using a top1 derivative of the protease-deficient strain JEL1 (30, 31) .
Oligonucleotide-directed Mutagenesis-Mutagenesis was carried out in a 50 ml PCR reaction with a Perkin-Elmer GeneAmp PCR System 9600 (Norwalk, CT) using QuikChange site-directed mutagenesis kit from Stratagene (La Jolla, CA). The formation of each mutation requires two complementary oligonucleotides containing desired mutation site. For the construction of T744P mutant, the following pair of oligonucleotides were used. The underlined nucleotides indicate the change from wild type yeast TOP2: 5Ј-CAG TCA TTG GCA CAA CCT ATT ATT GGG CTA GC-3Ј and 5Ј-GC TAG CCC AAT AAT AGG TTG TGC CAA TGA CTG-3Ј. For the construction of the T744A mutant, the following pair of oligonucleotides were used: 5Ј-CAG TCA TTG GCA CAA GCT ATT ATT GGG CTA GC-3Ј and 5Ј-GC TAG CCC AAT AAT AGC TTG TGC CAA TGA CTG-3Ј. For the construction of Q743P mutant, the following pair of oligonucleotides were used: 5Ј-GAG CAG TCA TTG GCA CCA ACT ATT ATT GGG C-3Ј and 5Ј-G CCC AAT AAT AGT TGG TGC CAA TGA CTG CTC-3Ј. The plasmid pDEDTOP2 (32) was used as the template in PCR reactions. The reaction mixture (50 l) contained 1ϫ reaction buffer (supplied by Stratagene), 20 ng of template DNA plasmid, 125 ng of each primer with desired mutation nucleotide(s), 10 nM dNTPs, and 2.5 units of Pfu DNA polymerase. PCR amplification used the following temperature regimes: one cycle of 95°C for 30 s and then 16 cycles of 95°C for 30 s, 55°C for 1 min, and 68°C for 24 min. To eliminate the wild type parental plasmid, the PCR products were then treated with 10 units of DpnI for 2 h at 37°C. DpnI is an endonuclease specific for methylated or hemimethylated guanine (G m6 ) and, presumably, should digest the parent template. One ml of the DpnI-treated PCR DNA was used to transform supercompetent XL1-Blue Epicurian coli cells (supplied by Stratagene). Bacterial colonies were selected and subsequently grown up on LB medium containing 100 g/ml of ampicillin. Plasmids were purified using QIAGEN-tip 100 (Santa Clarita, CA), as described by the manufacturer's protocol. All mutations mentioned above were verified by DNA sequencing.
Measurement of Drug Sensitivity in Yeast Cells-Drug sensitivity in yeast cells was carried out as described previously (26, (32) (33) (34) . Briefly, a logarithmically growing culture of yeast cells (grown in either YPDA (2% Bacto-peptone, 2% glucose, 1% yeast extract, 5 mg/liter adenine sulfate) or synthetic complete dropout medium as indicated) was diluted to 2 ϫ 10 6 cells/ml, and drug or Me 2 SO was added. Aliquots were removed, diluted, and plated either to YPDA plates or to synthetic complete dropout plates. Synthetic complete dropout plates lack one nutrient required for growth of the yeast strains used and were used to maintain selection for plasmids that complement the auxotrophy. For example, in experiments examining cell survival with cells carrying pMJ1, cells were plated to synthetic complete medium lacking uracil. Survival is expressed relative to the number of viable colonies at the time of drug addition. Drug sensitivity determinations were carried out at least three times for each strain, and representative results are shown.
Determination of Minimum Lethal Concentration-Minimum lethal concentration (mlc) was determined by extrapolating cell survival versus drug concentration curves and determining the point that gives 100% cell survival. Cell survival curves for mlc determination were all calculating using 24-h drug exposure.
Western Analysis of Yeast Topoisomerase II Levels-Western analysis of yeast Top2 proteins was carried out as described previously. 2 The yeast strains 394t2-4 pDEDTOP2 and 394t2-4 pDEDT744P were each inoculated into 200 ml of YPDA and grown at 30°C to an A 600 of 2.0. Cell pellets were lysed with glass beads and a bead beater. Protein concentrations were quantitated using the Bradford reagent (35) , and 100 and 250 g of protein from the total cell lysate were denatured and run on a 6% SDS-polyacrylamide gel. The proteins were transferred to a polyvinylidene difluoride membrane (Bio-Rad), and the membrane was incubated with 1:2500 anti-yeast TOP2 polyclonal antibody (Topogen) in phosphate-buffered saline plus 5% nonfat dried milk followed by incubation with a 1:2000 anti-rabbit Ig, horseradish peroxidase-linked secondary antibody (Amersham Pharmacia Biotech) in phosphate-buffered saline plus 0.1% Tween 20. The proteins were visualized by ECL (Amersham Pharmacia Biotech).
Overexpression and Purification of Yeast Topoisomerase II-Yeast topoisomerase II was expressed for purification using the plasmid pGAL1TOP2 (36) in yeast strain JEL1t1
Ϫ . Induction of Top2 by galactose and protein purification were as described previously (25, 26) .
Measurement of Topoisomerase II Activity-DNA topoisomerase II assays were carried out as described previously (26, 32, 37) . Briefly, the reaction mixture contained 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 50 mM KCl, 5.0 mM MgCl 2 , 2.5% glycerol, 0.5 mM ATP, 200 ng of pUC18, and the indicated amount of purified TOP2 protein. The reactions were incubated at 30°C for 30 min, subsequently stopped by addition of 1 l of 0.5 M EDTA into each reaction. The reactions were loaded onto an agarose gel, and after electrophoresis, the DNA was visualized by staining the gel with ethidium bromide and photographing under UV light. Decatenation assays used the same conditions except 100 ng of kDNA from Crithidia fasiculata was substituted for pUC18 plasmid DNA.
Determination of Drug Sensitivity of Purified Topoisomerase II-The K ϩ /SDS assay was used to determine drug stabilized DNA cleavage and was performed as described previously (26, 37) .
Measurement of Topoisomerase II Binding to DNA-Binding of topoisomerase II to DNA was performed using gel mobility shift assay as described previously with minor modifications (25, 38) . Briefly, a 10-l reaction volume containing 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 50 mM KCl, 2.5% glycerol, 88.5 ng of pUC18, and varying amounts of purified Top2 protein was incubated at 30°C for 6 min. The samples were then mixed with 1 l of loading buffer consisting of 60% sucrose and 0.67% orange G and subjected to electrophoresis using a 1% agarose gel in TAE buffer (0.04 M Tris acetate, 0.01 M EDTA). After electrophoresis at 6 volts/cm for 2.5 h, the gel was stained with ethidium bromide, visualized under UV light, and photographed. The DNA binds were quantitated using an IS-100 Digital Imaging System (Alpha Innotech Corporation, San Leandro, CA).
Molecular Dynamic Simulations-The coordinates for the 92-kDa wild type yeast topoisomerase II structure were obtained from the Brookhaven Protein Data Bank (accession number 1bgw). The Protein Data Bank file was edited to remove residues 410 -682, which includes the disordered linker region. Threonine 744 was replaced with proline using the Biopolymer module of the Insight II package (Molecular Simulations Inc.) on a Silicon Graphics workstation. All molecular dynamics simulations and energy minimizations were carried out using the SANDER module of the AMBER program, version 5.0 (Oxford Molecular). The T744P mutant was subjected to a 250-ps simulation (1-fs time step) at 310 K following a 40-ps equilibration cycle. The resulting structures were averaged and energy minimized. All graphics were constructed using Insight II (version 2.97/95.0).
RESULTS

Mutation of T744P Confers Hypersensitivity to Multiple
Classes of Topoisomerase II Poisons-The crystal structure of a 92-kDa fragment of yeast topoisomerase II indicated the presence of a helix-turn-helix domain (39) . Wang and colleagues (39) have suggested that the helix-turn-helix domain plays a critical role in DNA binding. This model of a structure of the yTOP2 protein, along with observations indicating that mutations within the helix-turn-helix altered sensitivity to topoisomerase II poisons, prompted us to construct a defined series of mutations in this domain. One mutagenesis strategy that we adopted changed residues in the helices of the domain to proline to test the effect of disrupting the secondary structures within this domain.
Thr 744 is in the middle of helix (the helix that is thought to be in the major groove of DNA. Oligonucleotide-directed mutagenesis changed Thr 744 to Pro in plasmid pDEDTOP2 (12) . The plasmid expresses yeast TOP2 from the yeast DED1 promoter and results in 10 -20-fold overexpression of the yeast enzyme. The mutagenized plasmid was transformed into strain JN394t2-4, which carries a temperature sensitive top2 allele. JN394t2-4 cells are unable to grow at 34°C, because of a lack of topoisomerase II activity at this temperature. Transformation with pDEDTOP2 (T744P) restored normal growth of JN394t2-4 cells at 34°C, indicating that the mutation did not eliminate top2 activity.
Because the only topoisomerase II active at 34°C is the top2 expressed from the plasmid, we next assessed the drug sensitivity of JN394t2-4 cells carrying the T744P mutant, compared with the same strain carrying an unmutagenized plasmid. Expression of T744P mutant resulted in a strain that was hypersensitive to the quinolone CP-115,953, a fluoroquinolone that is active against eukaryotic topoisomerase II (Fig. 1A and Table  I ). Approximately 2.7 M CP-115,953 was the mlc of drug with wild type yeast TOP2, and 0.6 M was the mlc with cells expressing the T744P allele. Similar results were seen with yeast cells exposed to the intercalating topoisomerase II poison amsacrine (Fig. 1B) . At 24 h, less than 1 M mAMSA is required for cell killing when cells express the T744P TOP2 mutant. The mlc of mAMSA for the mutant is approximately 0.6 M. By contrast, cell killing is only observed with about 5 M amsacrine when cells express wild type TOP2.
Because the T744P mutant was hypersensitive to the fluoroquinolone CP-115,953, we were interested in determining whether the mutant was also hypersensitive to other fluoroquinolones that are principally active against prokaryotic type II topoisomerases. T744P expressing cells were hypersensitive to the antibacterial fluoroquinolones ciprofloxacin (data not shown). This result suggests that the T744P mutant is hypersensitive to quinolones generally and not just CP-115,953.
A different result was obtained with the nonintercalating topoisomerase II poison etoposide. Yeast cells expressing either wild type TOP2 or the T744P mutant enzyme had comparable sensitivity to etoposide (data not shown). Although cell survival was consistently lower when cells expressing T744P were exposed to etoposide, compared with wild type cells, the differences in survival were not statistically significant, and no difference in the mlc was observed. This result suggests that the T744P mutant does not confer etoposide hypersensitivity. We previously showed that the level of drug sensitivity can depend on the level of active topoisomerase II protein and that an unstable topoisomerase II protein can lead to in vivo drug resistance (29) . Conversely, an abnormally stable protein could lead to drug hypersensitivity. The level of topoisomerase II protein was examined by Western blot. Fig. 2 shows the level of topoisomerase II polypeptides in yeast cells expressing Top2 proteins from the DED1 promoter. Although the levels of wild type and T744P proteins are similar, there is a slightly lower level of the T744P polypeptide. This suggests that the hypersensitivity is not due to enhanced stability of the T744P polypeptide.
To examine the biochemical properties of the T744P mutant, we introduced the T744P mutation into the plasmid pGALTop2 (36) , overexpressed the protein in yeast strain JELt1 Ϫ , and purified the mutant protein. The activity of the mutant protein was then compared with wild type topoisomerase II, by examining ATP-dependent relaxation of supercoiled plasmid DNA. Top2p carrying the T744P mutation has essentially the same specific activity for relaxation of supercoiled DNA as wild type Top2p (Fig. 3) . Similar levels of specific activity between wild type and Thr 744 Top2p were also seen when comparing the decatenation of kinetoplast DNA (data not shown).
We next examined levels of drug-dependent and drug-independent cleavage by K ϩ /SDS precipitation. In these assays, drug-induced cleavage was compared with DNA cleavage in the absence of drug for both wild type and T744P Top2 proteins. Data for the drug-independent cleavage for this series of experiments were pooled to compare the level of drug-independent cleavage of the wild type and mutant proteins. To account for the different specific activities of the 32 P-labeled DNA substrate prepared on different days, we determined the ratio of drug-independent cleavage with T744P protein to the drugindependent cleavage with wild type topoisomerase II, where the measurements with both enzymes were carried out with the same batch of substrate. This ratio was 1.09 Ϯ 0.22 (mean Ϯ S.D., n ϭ 11). The 95% confidence interval was 0.94 -1.24. These results suggest that there was not a significant difference in drug-independent cleavage between the T744P and wild type topoisomerase II proteins.
We next compared the level of DNA cleavage obtained with wild type and Thr 744 topoisomerase II in the presence of topoisomerase II poisons. Fig. 4A shows the DNA cleavage obtained at low mAMSA concentrations, and Fig. 4B shows the results obtained at higher drug concentrations. Enhanced cleavage can be clearly seen at low mAMSA concentrations. The mAMSA concentration required to increase the drug-independent cleavage by a factor of two is approximately 0.15 M for the T744P protein and 0.64 M with wild type topoisomerase II. There is less difference between the two proteins at higher drug concentrations. At 50 M, there is approximately a 2-fold difference in the level of cleavage between the two proteins.
A similar result was obtained with CP-115,953. DNA cleavage in the presence of CP-115,953 is shown in Fig. 5 . A drug concentration of 0.3 M doubles DNA cleavage over drug-independent levels with the T744P protein, whereas approximately 3 M is required to double DNA cleavage with wild type Top2p. A smaller difference is seen at 10 M drug, where the fold stimulation differs between the two proteins by a factor of two.
Results obtained from drug cytotoxicity measurements suggested that the T744P mutant would not show enhanced cleavage in the presence of etoposide. The experiment shown in Fig.  6 bears out this prediction. Etoposide-stimulated cleavage is essentially identical between the T744P and wild type Top2p at all etoposide concentrations examined. Taken together, results with the purified T744P protein demonstrate the same pattern of drug sensitivity predicted from in vivo cytotoxicity measurements.
FIG. 2. Western analysis of T744P expression.
Total cell extracts were prepared from JN394t2-4 cells carrying either pDEDTOP2 or pDEDTOP2 T744P. Proteins were separated using SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was probed with antibody directed against yeast TOP2. Protein concentrations are indicated on the figure. WT, wild type.
FIG. 3. Catalytic activity of T744P topoisomerase II protein.
The catalytic activities of wild type and T744P proteins were compared using ATP-dependent relaxation of pUC18. Different quantities of purified protein were added as indicated on the figure. After electrophoresis, the gel was stained with ethidium bromide, and bands were visualized under UV light. WT, wild type.
FIG. 4.
Covalent complex formation by T744P in the presence of mAMSA. The K ϩ /SDS assay was used to assess quantitative levels of DNA cleavage in the presence of a Top2 poison (37, 45, 46) . Cleavage reactions contained 25 units (500 ng) of Top2p, ␣-32 P end-labeled pUC18 (digested with EcoRI and then filled by Klenow fragment of E. coli DNA polymerase I with [␣-32 P]dATP) and the indicated concentrations of mAMSA. Reactions were terminated with SDS, and proteins were precipitated with KCl. After washing, the level of radioactive DNA co-precipitating with proteins was determined by scintillation counting. A, K ϩ /SDS assay of at low concentrations of mAMSA. B, K ϩ /SDS assay of cleavage stabilized by a broad range of mAMSA concentrations.
We also examined the effect of a more potent intercalating topoisomerase II poison, mitoxantrone. Mitoxantrone, like other strong intercalating agents, shows a sharp maximum in the level of cleavage at relatively low drug concentrations. At higher drug concentrations, DNA cleavage is inhibited. Both wild type and T744P proteins show identical maxima at 0.45 M mitoxantrone (Fig. 7) . The concentration of mitoxantrone required to double DNA cleavage was about 0.1 M with the T744P protein and about 0.2 M with wild type Top2p. The level of maximal level of cleavage was also slightly higher with the T744P mutant protein. The T744P protein also shows slightly more inhibition of cleavage at higher mitoxantrone concentrations. This result shows that the T744P mutant was also hypersensitive to other intercalating agents.
In vivo cytotoxicity measurements showed that the T744P mutant was hypersensitive to the fluoroquinolone ciprofloxacin. We examined the levels of DNA cleavage with different fluoroquinolones that are selective for prokaryotic topoisomerase II. The results are summarized in Table II . The T744P mutant protein showed higher levels of DNA cleavage with the fluoroquinolones ciprofloxacin and norfloxacin and with the quinolone oxolinic acid. The greatest difference in potency was seen with oxolinic acid, where 76 M oxolinic acid doubled DNA cleavage with the T744P protein, whereas the level of cleavage did not increase 2-fold with wild type topoisomerase II at 2,000 M oxolinic acid, a greater than 26-fold difference in potency. These results show that the T744P protein is hypersensitive to multiple classes of intercalating agents and fluoroquinolones but not to all classes of topoisomerase II poisons.
Previous studies with the S740W mutant of yeast TOP2 showed an association between etoposide hypersensitivity and heat-and salt-stable covalent protein-DNA complexes. To test whether a similar mechanism of drug hypersensitivity was occurring in the T744P mutant, the heat stability of the covalent complexes formed was assessed. DNA cleavage assays were performed as above, except the reactions were incubated at 65°C for various periods of time. The reactions were stopped by the addition of SDS, and levels of cleavage were determined. The results are shown in Fig. 8 . Heat readily reverses covalent complexes formed by the T744P mutant in the presence of mAMSA, CP-115,953, or etoposide. Heat reversal with etoposide is somewhat less than observed with the other two agents, consistent with some degree of heat stability seen with the wild type protein and etoposide. For comparison, the level of heatstable covalent complexes formed with the S740W protein in the presence of etoposide is also shown in Fig. 8 . We conclude that the drug hypersensitivity associated with the T744P mutant protein is not associated with more stable covalent complexes.
The results presented above demonstrate that mutating Thr 744 to Pro results in a drug-hypersensitive Top2p. To dis- 
TABLE II
Activity of quinolones against wild type and T744P Top2 proteins C 2 is the concentration of drug required to double the level of precipitable counts over drug-independent levels. Maximal cleavage is the fold increase in precipitable counts over drug independent levels at C m , the highest drug concentration tested. tinguish between effects on secondary structure and the chemical nature of the side chain, Thr 744 was changed to Ala, an amino acid that tends not perturb ␣ helices. As above, the mutation was constructed in pDEDTOP2, and sensitivity to mAMSA, etoposide, and CP-115,953 was determined. Table I shows the sensitivity of T744A to mAMSA and CP-115,953 after 24 h of drug exposure. Slight hypersensitivity to the fluoroquinolone CP-115,953 was observed. The minimum lethal concentration was 2.7 M for wild type TOP2 and 1.5 M for the T744A mutant. The sensitivity of the T744A mutant to mAMSA was essentially unchanged compared with wild type TOP2. Therefore, the T744A mutant did not result in the same degree of sensitization as was observed with the T744P mutant. This result suggests that the alteration of the secondary structure because of the mutation to Pro is responsible at least in part for the phenotype seen with T744P.
A possible alteration in the secondary structure that could be caused by the mutation of Thr 744 to Pro is a complete destabilization of the ␣ 4 helix. If so, then a mutation of an adjacent residue to Pro would be expected to generate a protein with similar biochemical properties. A mutation was constructed in pDEDTOP2 that changes amino acid 743 to Pro. Sensitivity to mAMSA and CP-115,953 was assessed in cells expressing Q743P (Table I) . Unlike what is observed with the T744P mutant, changing Gln 743 to Pro results in slight resistance to both CP-115,953 and mAMSA. This result suggests that changing T744P leads to a specific change that leads to drug hypersensitivity.
Because the Thr 744 mutation occurs in a domain of topoisomerase II that has been implicated in DNA binding, the observed effects on drug sensitivity could arise in part from a change in the affinity of the protein for DNA. We tested DNA binding affinity using an electrophoretic mobility shift assay, using supercoiled pUC18 DNA as a substrate (25, 38) . Fig. 9 shows the result of this assay carried out with wild type or T744P topoisomerase II proteins. Addition of 160 ng of either protein results in a retardation of mobility, with correspondingly greater retardation of mobility at higher protein concentrations. Fig. 9B shows a quantitation of the mobility shift shown in Fig. 9A . There is no significant difference between wild type and T744P topoisomerase II proteins. These results indicate that the T744P mutation does not lead to a quantitative alteration in DNA binding.
To assess specific molecular changes that arise from the T744P mutation, we carried out molecular dynamics simulations based on the structure reported by Berger and colleagues (39) carrying a T744P substitution. The simulations of the T744P mutant show an overall conservation of the enzyme structure. Fig. 10 shows the structure of 91-kDa fragment structure described by Berger and colleagues (39) . Fig. 11 highlights the changes predicted to occur in the region around the ␣ 4 helix based on the molecular dynamics simulation. As expected, the ␣ 4 helix is disrupted by the replacement of Thr with Pro, resulting in a kink in the helix. The structure obtained in Fig. 11 was then used as a starting point in a molecular dynamic calculation, changing Pro 744 back to Thr. The resulting structure fit well with the starting structure determined by Berger and Wang and colleagues (39) .
Interestingly, a change in the vicinity of the active site tyrosine (Tyr 782 ) is also seen in the T744P mutant. Tyr 782 and Arg 781 in wild type Top2p (shown in Fig. 11 complement a temperature sensitive top2 mutation and a protein with 10 -100 fold reduction in activity in vitro. (41, 42) . Other agents, such as fluoroquinolones, do not inhibit religation and therefore stimulate covalent complex formation by increasing the rate of cleavage by the enzyme (11) . Interestingly, the mutant we describe in this work can cause hypersensitivity to both classes of topoisomerase II poisons.
Several mechanisms can be envisioned that would lead to a drug-hypersensitive topoisomerase II protein. A simple mechanism is an increased affinity by the protein for the drug. A previously described mutation that confers resistance to CP-115,953 is hypersensitive to ellipticines (25) . Osheroff and colleagues (43) subsequently showed that the mutant protein has a higher affinity for ellipticines in the absence of DNA. However, it is difficult to imagine an increased affinity for chemically distinct agents, as we observed for the T744P mutant protein. Nonetheless, if quinolones are able to interact with DNA in a manner similar to that of intercalating agents, then this mechanism would be a plausible interpretation for the drug hypersensitivity of the T744P mutant protein. Binding of fluoroquinolones to DNA has been suggested, but the precise mode of binding remains controversial.
A second mechanism for drug hypersensitivity is a change in the stability of the covalent protein-DNA complex. Mutation of S740W results in an etoposide-hypersensitive protein. Unlike wild type Top2p, the covalent complexes formed in the presence of etoposide are stable with respect to high salt or exposure to 65°C, whereas covalent complexes formed in the absence of drug or the presence of a different complex stabilizing drug are heat-and salt-labile (26) . We found no evidence for increased heat stability of the covalent complexes formed in the presence of any of the topoisomerase II poisons examined. Thus, the specific mechanism of drug hypersensitivity is likely to differ between the S740W mutant and the T744P mutant.
The molecular dynamics modeling of topoisomerase II suggests a simple model that may explain at least part of the drug hypersensitivity seen in the T744P mutant. The displacement of Arg 781 by the T744P mutant may affect the cleavage/religation equilibrium to favor the cleaved state. It could do so in two different ways. First, if Arg 781 participates in the cleavage and religation reactions, then its displacement toward Gln 739 would make it less available to participate in religation. Second, the presence of DNA and drug may constrain the residue so that it remains close to Tyr 782 . In this case, Tyr 782 , when it is covalently bound to DNA, could be displaced away from the 3Ј-hydroxyl group, again reducing the rate of religation. Overall, this model suggests that drug sensitivity is altered by displacing amino acids that play a critical role in cleavage and religation by topoisomerase II.
A recent new structure of topoisomerase II has led to the hypothesis that substantial movement by the enzyme during the process of cleavage and strand passage allows residues that are distant from the active site tyrosine at some points in time to affect drug sensitivity by their movement toward the active site tyrosine and their participation in the cleavage reaction (44) . Because our analysis has relied mainly on the Berger and Wang structure (39) , there may be other key residues that are displaced by the T744P mutation. Nonetheless, an appealing model for drug action is the displacement of key residues that are involved in catalysis. Because the ligation of DNA breaks probably involves a reversal of the cleavage reaction, residues that are important for DNA cleavage are probably also required for religation. The presence of bound drug may allow the residues to function in DNA cleavage, but after cleavage, the presence of drug may cause the residues to be displaced so that they are not properly positioned for participation in religation. Drugs binding at different sites on the enzyme would not move key residues in the same way. Thus, we would suggest important differences in the drug-binding sites of etoposide versus quinolones or intercalating agents. More detailed information about the sites of drug binding will provide a test for this model.
The work described here highlights the conservation of drug mechanisms between eukaryotic and prokaryotic type II topoisomerases. We have described a single amino acid change that allows quinolones that are highly specific for prokaryotic Top2 to have substantial activity against eukaryotic Top2. We suggest that the quinolone-binding domains between the eukaryotic and prokaryotic enzymes are extremely similar, with only small changes preventing quinolones active against prokaryotic enzymes from acting against eukaryotic Top2. Given the importance of quinolones as anti-bacterial agents, understanding what factors prevent the interaction of quinolones with eukaryotic Top2 will be an important element in anti-bacterial drug design.
